To evaluate the status of TILs after combination (IL-15, NIR-PIT) therapy and anti-PD-1 therapy, we analyzed the CD8+ T cells and Treg distribution inside the tumor tissue 4 days after NIR-PIT using immunohistochemical analysis. The gene discussed is IL15; the disease is neoplasm.